Telesta raises $28.6M in private placement
Telesta Therapeutics Inc. (TSX:TST; Pink:BNHLF) raised $28.6 million through the sale of 109 million shares at C$0.34 ($0.26) in a private placement led by Consonance Capital Investors; Boxer Capital of Tavistock Life Sciences; and Omega Funds. Members of Telesta's senior management team and board also participated. Ladenburg Thalmann was the lead placement agent and Roth Capital Partners and Euro Pacific Canada were co-placement agents.
Telesta submitted a BLA to FDA in June for MCNA ( EN3348) to treat high-risk non-muscle invasive bladder cancer in patients who have failed first-line treatment with bacillus Calmette-Guerin (BCG) therapy. The company is seeking Priority Review for the application. MCNA is a mycobacterial cell wall-DNA complex (MCC). ...